Your prediction
Pluristem Therapeutics Inc. Stock
Our community identified positive and negative aspects for Pluristem Therapeutics Inc. stock for the coming years. 1 users see the criterium "Revenue growth" as a plus for the Pluristem Therapeutics Inc. stock. On the other hand our users think that "EBIT growth" could be a problem in the future.
Pros and Cons of Pluristem Therapeutics Inc. in the next few years
Pros
?
C******** o* t** e**********
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Pluristem Therapeutics Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Pluristem Therapeutics Inc. | - | - | - | - | - | - | - |
| Enlivex Therapeutics Ltd. | -1.040% | 3.243% | 7.303% | -4.500% | 56.557% | -73.921% | -90.905% |
| Oramed Pharmaceuticals | -0.800% | -9.137% | -2.253% | 42.417% | 18.103% | 42.701% | -55.871% |
| Formycon AG | 2.790% | -3.728% | -4.772% | -14.591% | -14.090% | -71.859% | -64.936% |